FDA Approves Novocure’s Optune Lua for Metastatic NSCLC After Platinum-Based Chemotherapy

Oct 15, 2024, 06:35 PM

The US FDA has approved Novocure's Optune Lua for the treatment of metastatic non-small cell lung cancer (mNSCLC). The approval allows Optune Lua to be used concurrently with PD-1/PD-L1 inhibitors or docetaxel for adult patients who have progressed on or after a platinum-based chemotherapy regimen. This decision is based on the results of the LUNAR study, which showed a statistically significant improvement in overall survival. The study was presented at ASCO in 2023. The approval is expected to positively impact Novocure's market cap. $NVCR shares are anticipated to see an uptick following the FDA approval.